Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Net Cash Flow (2016 - 2025)

Cytosorbents (CTSO) has disclosed Net Cash Flow for 14 consecutive years, with -$2.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 11.85% year-over-year to -$2.5 million, compared with a TTM value of -$3.1 million through Sep 2025, down 242.94%, and an annual FY2024 reading of -$5.8 million, up 28.96% over the prior year.
  • Net Cash Flow was -$2.5 million for Q3 2025 at Cytosorbents, down from -$1.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $5.7 million in Q4 2023 and bottomed at -$12.7 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$3.3 million, with a median of -$2.9 million recorded in 2021.
  • The sharpest move saw Net Cash Flow tumbled 340.15% in 2022, then surged 1137.17% in 2023.
  • Year by year, Net Cash Flow stood at -$7.2 million in 2021, then soared by 92.46% to -$546406.0 in 2022, then soared by 1137.17% to $5.7 million in 2023, then crashed by 140.56% to -$2.3 million in 2024, then dropped by 9.72% to -$2.5 million in 2025.
  • Business Quant data shows Net Cash Flow for CTSO at -$2.5 million in Q3 2025, -$1.6 million in Q2 2025, and $3.3 million in Q1 2025.